Results

Total Results: 258 records

Showing results for "end stage renal".

201. Single-arm studies in comparative effectiveness reviews (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/single-group-studies_white-paper.pdf
     January 01, 2013 - For example, in patients with end-stage liver disease, the natural history of disease is so well known … We excluded CERs at the draft stage at the time of the last search because draft reports have not been … As an example, the change in blood pressure is assessed in patients with renal artery stenosis before … For example, there may be variability in the stage of disease presentation of pathological features

202. Noninvasive Testing for Coronary Artery Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/coronary-artery-disease-testing_research-protocol.pdf
     January 15, 2015 - • Harms, risks and consequences of testing o Procedural harms, adverse events of testing (e.g., renal … Harms, risks and consequences of testing (both initial and subsequent testing) • Harms of testing (renal … Thus, to set the stage for the review’s Key Questions, which are focused on clinical decisionmaking … Key Informants Key Informants are the end users of research, including patients and caregivers, practicing … Because of their role as end-users, individuals are invited to serve as Key Informants and those who

203. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1312.pdf
     January 01, 2016 - ITCA 650 pump system compared with twice-daily exenatide injections (Ex-BID) was evaluated in a two-stage … Stage II (n=131) re-randomly assigned patients to receive 20, 40, 60, or 80 mcg/day of ITCA 650 for … Stage I: mean change in HbA1c from a mean baseline of 7.9-8.0% was -0.98, -0.95, and -0.72% for the … Stage II: significant (P < 0.05) reductions in HbA1c (∼1.4% from baseline) were achieved with 60 and … This would require more patient followup to monitor renal function.

204. FRN 29: Future Research Needs on Procalcitonin-Guided Antibiotic Therapy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/procalcitonin-future_research.pdf
     August 01, 2014 - Changes in outcomes from the beginning to the end of the study are compared across groups. … To that end, stratification may be needed to assess the contribution of procalcitonin in populations … Changes in outcomes from the beginning to the end of the study are compared across groups. … For patients with underlying stable chronic disease (e.g. diabetes, renal disease, but excluding immunocompromised … diabetes, renal disease, but excluding immunocompromised patients) and a high uncertainty of infection

205. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1306.pdf
     January 01, 2016 - evaluated in a randomized phase II trial in patients with T2DM inadequately controlled with metformin.47 Stage … For Stage II, 131 subjects were re-randomly assigned to receive 20, 40, 60, or 80 mcg/day of ITCA 650 … Stage I: mean change in HbA1c from a mean baseline of 7.9-8.0% was -0.98, -0.95, and -0.72% for the … Stage II: significant 9 (P < 0.05) reductions in HbA1c (∼1.4% from baseline) were achieved with … This expert added that prescribing providers would need to be willing to monitor renal function in

206. Draft Appendixes: Malnutrition in Hospitalized Adults (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/malnutrition-hospitalized-adults-draft-appendixes.pdf
     April 08, 2021 - There were no restrictions in terms of age, ethnicity, or type or stage of cancer. 8 trials of … among studies of SGA NR Inpatient Mean: 52 % Male: 67.2% NR NR Cirrhosis Model for End … Stage Liver Disease (MELD): 14.8 Child‐Pugh (CP): 26% CP A, 41.6% was CP B and 32.5% was CP C … Included patients aged 75 or older admitted for acute conditions between November 1999 and end of … Excluded patients with a medical condition preventing oral feeding, end-of-life patients, patients

207. Mass-Casualty-Events-Scarce-Resources Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mass-casualty-events-scarce-resources_executive.pdf
     June 01, 2012 - Each used a vastly different strategy and examined effectiveness using different end points. … rather than intervention studies, and only a few of these examined similar scenarios using similar end … available resources Medical interventions (2 studies) • Medical interventions for the prevention of acute renal … Time-based Triage) • Triage strategies (e.g., combining triage categories, adding categories, one- vs. two-stage

208. A Prospective Comparison of Evidence Synthesis Search Strategies Developed With and Without Text-Mining Tools (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-results-search-strategies-developed-with-without-text-mining-tools.pdf
     March 01, 2021 - Aromatherapy and Essential Oils: A Map of the Evidence25 Simple PubReminer, Yale MeSH Analyzer, Carrot2 End-stage … Renal Disease and Depression: A Systematic Review* Simple PubReminer, Carrot2, VOSviewer Gulf War … Tool | Web-Based Tool) MeSH on Demand is a National Library of Medicine (NLM) designed to analyze end-user … PubReMiner (Keyword/Phrase and Subject Term Tool | Web-Based Tool) PubReMiner analyzes end-user defined … I still find Carrot2 more useful for this stage as it clumps the references into topics, but I did

209. Use of and access to health care by Medicare beneficiaries with diabetes: impact of diabetes type and insulin use, 2007-2011 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-medicare-use_research.pdf
     January 01, 2014 - Hispanic ethnicity.13,14 Age: The age categories were defined us- ing the age of the beneficiary at the end … *End stage renal disease (ESRD) is a subset of CKD. In 2011, 6.2% of CKD beneficiaries had ESRD.

210. Heart-Failure-Transition-Care Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-transition-care_executive.pdf
     May 01, 2014 - readmissions within 30 days were for HF; the remainder of readmissions were for diverse indications (e.g., renal … that 35 percent of 30-day readmissions are for HF; the remainder are for diverse indications (e.g., renal … Included trials commonly excluded patients who had end-stage renal disease or severe or unstable cardiovascular

211. Research Protocol: Safety of Vaccines Used for Routine Immunization in the United States (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/safety-vaccines-protocol.pdf
     January 30, 2020 - transplantation : official publication of the European Dialysis and Transplant Association - European Renal … Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage … renal disease population unresponsive to primary vaccination series. … Renal failure. 2015;37(7):1080-8. 105. Zafack JG, De Serres G, Kiely M, et al. … Nervous system disorders • Pregnancy, puerperium and perinatal conditions • Psychiatric disorders • Renal

212. Defining an Optimal Format for Presenting Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-future-presentation-format_research.pdf
     January 01, 2019 - The interviewer identified themes after the end of each interview based on the discussions with the … rare harmful effects in randomized controlled trials 2006 JAMA 20197533 Higher vs lower positive end-expiratory … 17261117 Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage … renal disease: evidence for coverage decisions in Thailand 2007 Value Health 18263560 Identifying … groundwater remediation system 2008 Sci Total Environ 18697843 Determining optimal sample sizes for multi-stage

213. Comparative Effectiveness of Noninvasive Technologies for the Diagnosis of Coronary Artery Disease (CAD) in Women | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/cad-women-diagnosis/research-protocol
     December 08, 2010 - contrast agent used during the procedure to visualize the coronary arteries may cause anaphylaxis or renal … Lesser increase in the left ventricular ejection fraction Increase in cardiac output by enhancing end-diastolic … KQ 4: Nephrogenic systemic fibrosis was added as an adverse event associated with late-stage chronic

214. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-insulin_executive.pdf
     September 01, 2008 - agents in patients with type 2 diabetes, insulin is required in a significant number of patients at some stage … based on few absolute events in only a few studies, in which clinical outcomes were not the primary end … All trials either excluded patients with cardiac, renal, or hepatic disease or did not report whether

215. Evidence Map on Home and Community-Based Services (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-map-hcbs-draft-technical-brief.pdf
     December 07, 2023 - Because of their role as end-users, individuals with potential conflicts may be retained. … conditions, and people with specific conditions, most commonly Parkinson’s disease, Alzheimer’s disease, or end-stage … conditions, and people with specific conditions, most commonly Parkinson disease, Alzheimer disease, or end-stage … older adults with Parkinson’s disease,53 dementia,33, 41, 42, 45, 46, 58 intellectual disabilities,50 end-stage … renal disease on home dialysis,32, 38, 54 terminal illness,37 multiple chronic diseases,35, 39 or,

216. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/10_obesity_potential_high_impact_2012-12-11.pdf
     January 01, 2012 - . * EndoBarrier Endoluminal Sleeve for treatment of obesity and/or type 2 diabetes Lower end of the … also increases the risk of several types of cancer including colorectal, endometrial, esophageal, renal …  Potential for High Impact: Lower end of the high-potential-impact range 1 Obesity Interventions … Based on this input, our overall assessment is that this intervention is in the high end of the high-potential-impact … Based on this input, our overall assessment is that this intervention is in the lower end of the high-potential

217. Infectious Disease Including HIV/AIDS #09 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/infectious-disease-horizon-scan-high-impact-1512.pdf
     January 28, 2016 - (e.g., those who have experienced prior treatment failures, who have advanced cirrhosis, who have renal … chronic HCV genotype 4 infection and for treating patients with chronic HCV genotype 1 infection with end-stage … renal disease on hemodialysis. … HCV genotype 4 infection and another for treating chronic HCV genotype 1 infection in patients with end-stage … renal disease on hemodialysis.23 Merck submitted a new drug application for treating chronic HCV genotype

218. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
     January 01, 2015 - you couldn't fiugre out which and stratify by comparator Correct, we have added text to clarify at end … and Brand names of the FDA-approved members of the class, at least those drugs available as of the end … Use of metformin in the setting of mildtomoderate renal insufficiency. Diabetes Care. … Use of metformin in the setting of mildtomoderate renal insufficiency. … stage renal disease) a.

219. Obesity (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/obesity_hi_impact.pdf
     April 17, 2012 - also increases the risk of several types of cancers including colorectal, endometrial, esophageal, renal … In December 2010, Arena Pharmaceuticals announced a plan to resubmit the lorcaserin NDA by the end … phentermine plus topiramate combination is administered daily as an oral medication. 15 In late-stage … treatment of obesity this input, our overall assessment is that these interventions are in the higher end … Based on this input, our overall assessment is that this intervention is in the lower end of the high

220. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/cad-women-diagnosis_research-protocol.pdf
     June 06, 2011 - contrast agent used during the procedure to visualize the coronary arteries may cause anaphylaxis or renal … Lesser increase in the left ventricular ejection fraction Increase in cardiac output by enhancing end-diastolic … KQ 4: Nephrogenic systemic fibrosis was added as an adverse event associated with late-stage chronic